Elizabeth Sarmiento
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elizabeth Sarmiento has a total of 225 co-authors. Here are the top co-authors by number of shared publications:
- Javier Carbone
Clinical Immunology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
57 shared publications J. Palomo
Cardiology Department; Hospital General Universitario Gregorio Marañón; Madrid Spain
11 shared publicationsJoaquin Navarro
Transplant Immunology Group, Immunology Department, Hospital General Universitario Gregorio Marañon, Instituto de Investigacion Sanitaria Gregorio Marañon, Immunology Department, School of Medicine, Complutense University, Madrid, Spain
11 shared publicationsAntonio Gallego
Servicio de Inmunología, Hospital General Universitario Gregorio Marañón, Madrid, Spain
10 shared publicationsE. Fernández-Cruz
9 shared publicationsNallibe Lanio
Clinical Immunology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Microbiology Department, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
7 shared publications
Latest Publications
- Open Access
- 4 March 2026
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 12 (4) , e1928
Evaluation of IVIG for Prevention of Infections Occurring On-study and Treatment of Infection of Solid Organ Recipients With Secondary Antibody Deficiency: A Phase 2 Randomized Clinical Trial
Background.: There is a paucity of data to guide the management of posttransplant secondary antibody deficiency (SAD). We aimed to evaluate the role of IVIG in solid organ recipients with SAD. Methods.: A phase 2, randomized, multicenter, open-label study of solid organ recipients with severe infection and SAD defined as serum IgG P = 0.012). The median number of infections occurring on-study was lower in the IVIG group. The median total number of new admissions considered to be related to an infection occurring on-study was significantly lower in IVIG-treated patients. A significant increase in specific anti-cytomegalovirus IgG, anti–varicella zoster IgG, anti- Clostridium difficile toxins A and B IgG, and anti-tetanus toxoid IgG and IgG1 was demonstrated in the IVIG arm. Conclusions.: In solid organ recipients with severe infection and SAD, IVIG may reduce infection occurring on-study occurrence versus SOC.
- 4 March 2026
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 12 (4) , e1928
Open AccessEvaluation of IVIG for Prevention of Infections Occurring On-study and Treatment of Infection of Solid Organ Recipients With Secondary Antibody Deficiency: A Phase 2 Randomized Clinical Trial
Background.: There is a paucity of data to guide the management of posttransplant secondary antibody deficiency (SAD). We aimed to evaluate the role of IVIG in solid organ recipients with SAD. Methods.: A phase 2, randomized, multicenter, open-label study of solid organ recipients with severe infection and SAD defined as serum IgG P = 0.012). The median number of infections occurring on-study was lower in the IVIG group. The median total number of new admissions considered to be related to an infection occurring on-study was significantly lower in IVIG-treated patients. A significant increase in specific anti-cytomegalovirus IgG, anti–varicella zoster IgG, anti- Clostridium difficile toxins A and B IgG, and anti-tetanus toxoid IgG and IgG1 was demonstrated in the IVIG arm. Conclusions.: In solid organ recipients with severe infection and SAD, IVIG may reduce infection occurring on-study occurrence versus SOC.
- Open Access
- 31 December 2024
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 30, e946233
A New Routine Immunity Score (RIS2020) to Predict Severe Infection in Solid-Organ Transplant Recipients
A New Routine Immunity Score (RIS2020) to Predict Severe Infection in Solid-Organ Transplant Recipients - Article abstract #946233
- 31 December 2024
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 30, e946233
Open AccessA New Routine Immunity Score (RIS2020) to Predict Severe Infection in Solid-Organ Transplant Recipients
A New Routine Immunity Score (RIS2020) to Predict Severe Infection in Solid-Organ Transplant Recipients - Article abstract #946233
- 1 November 2021
- Published by Elsevier in Transplantation Proceedings
- Vol. 53 (9) , 2724-2727
Immunologic Abnormalities Associated With Health Status of Heart Recipients Long Term After Transplantation
- 1 November 2021
- Published by Elsevier in Transplantation Proceedings
- Vol. 53 (9) , 2724-2727
Immunologic Abnormalities Associated With Health Status of Heart Recipients Long Term After Transplantation
- 1 August 2018
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 37 (8) , 1001-1012
Monitoring of early humoral immunity to identify lung recipients at risk for development of serious infections: A multicenter prospective study
- 1 August 2018
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 37 (8) , 1001-1012
Monitoring of early humoral immunity to identify lung recipients at risk for development of serious infections: A multicenter prospective study
- 1 July 2018
- Published by Wolters Kluwer Health in Transplantation
- Vol. 102 (Supplement) , S359
IgG Hypogammaglobulinemia is a Risk Factor of Cytomegalovirus Infection in a Multicenter Study in Kidney Transplantation
IgG hypogammaglobulinemia has been demonstrated as a risk factor of severe infection in solid organ tranplantation in single center studies and metanalysis. Kidney transplant patients are more prone to CMV infection due to immunosuppressive therapy. IgG testing is suggested when CMV is difficult to control. We here present the results of a multicenter study with the aim to evaluate distinct humoral immunity biomarkers as potential predictors of CMV infection. In a prospective multicenter study of a cohort of 212 patients in 2 centers in Spain who underwent kidney transplantation we identified patients who developed CMV infection during a 6 month follow-up after transplantation. Levels of IgG, IgM, IgA and complement C3 and C4 were prospectively measured in both centers using the routine laboratory. Assessment times were before transplantation, at day 7 and at day 30 after transplantation. Logistic regressión analysis was performed to assess potential biomarkers. During follow up 18 (8.5%) kidney recipients developed at least one episode of CMV infection. Day 30 IgG level was lower in patients who developed CMV infections after transplantation compared to patients without this complication (704±276 and 894±281%, respectively, p = 0.013). IgG level <700 mg/dL (IgG hypogammaglobulinemia) was significantly associated with risk for development of CMV infection in logistic regression analysis, RH 3.33, 95% CI 1.05-10.48, p = 0.04. Patients with hypogammaglobulinemia also disclosed a higher risk of developing recurrent infections (defined as 3 or more episodes caused by distinct pathogens, 24.1%), RH 2.4, 95% CI, 1.12-4.95, p=0.024). The results obtained in this multicenter study suggest that lower levels of IgG are a risk factor for development of CMV infection and recurrent infections in kidney transplantation. IgG assessmnent is easily available, rapid and low cost. The inclusion of this biomarker in immunomonitoring protocols should be taken into account as well as in clinical guidelines. Fondo de Investigacion Sanitaria. Project FIS 1501472. With participation of FEDER Funds, a new way of making Europe. ISR global grant Grifols, California, USA.
- 1 July 2018
- Published by Wolters Kluwer Health in Transplantation
- Vol. 102 (Supplement) , S359
IgG Hypogammaglobulinemia is a Risk Factor of Cytomegalovirus Infection in a Multicenter Study in Kidney Transplantation
IgG hypogammaglobulinemia has been demonstrated as a risk factor of severe infection in solid organ tranplantation in single center studies and metanalysis. Kidney transplant patients are more prone to CMV infection due to immunosuppressive therapy. IgG testing is suggested when CMV is difficult to control. We here present the results of a multicenter study with the aim to evaluate distinct humoral immunity biomarkers as potential predictors of CMV infection. In a prospective multicenter study of a cohort of 212 patients in 2 centers in Spain who underwent kidney transplantation we identified patients who developed CMV infection during a 6 month follow-up after transplantation. Levels of IgG, IgM, IgA and complement C3 and C4 were prospectively measured in both centers using the routine laboratory. Assessment times were before transplantation, at day 7 and at day 30 after transplantation. Logistic regressión analysis was performed to assess potential biomarkers. During follow up 18 (8.5%) kidney recipients developed at least one episode of CMV infection. Day 30 IgG level was lower in patients who developed CMV infections after transplantation compared to patients without this complication (704±276 and 894±281%, respectively, p = 0.013). IgG level <700 mg/dL (IgG hypogammaglobulinemia) was significantly associated with risk for development of CMV infection in logistic regression analysis, RH 3.33, 95% CI 1.05-10.48, p = 0.04. Patients with hypogammaglobulinemia also disclosed a higher risk of developing recurrent infections (defined as 3 or more episodes caused by distinct pathogens, 24.1%), RH 2.4, 95% CI, 1.12-4.95, p=0.024). The results obtained in this multicenter study suggest that lower levels of IgG are a risk factor for development of CMV infection and recurrent infections in kidney transplantation. IgG assessmnent is easily available, rapid and low cost. The inclusion of this biomarker in immunomonitoring protocols should be taken into account as well as in clinical guidelines. Fondo de Investigacion Sanitaria. Project FIS 1501472. With participation of FEDER Funds, a new way of making Europe. ISR global grant Grifols, California, USA.
- 1 July 2018
- Published by Wolters Kluwer Health in Transplantation
- Vol. 102 (Supplement) , S84
Intravenous Immunoglobulin Replacement Therapy in Solid Organ Transplantation with Severe Infections and Secondary Antibody Deficiency
Background Secondary antibody deficiency is a risk factor of severe infection in solid organ transplantation. Very few studies have previously evaluated the potential role of IgG replacement in solid organ recipients with IgG hypogammaglobulinemia (HGG) at the time of a severe infectious complication. We evaluated the impact of therapeutic intervention of intravenous immunoglobulin (IVIG) in solid organ recipients with severe infections and HGG on clinical outcomes. Methods Retrospective analysis of prospectively collected data of 60 patients in a single center. All patients were hospitalized because of severe infections or developed a severe infection during a hospitalization in the post-transplantation period (June 2015-June 2017) and were found to have HGG (serum IgG750 mg/dL) and 28 patients were treated with only conventional antimicrobial therapy. IVIG was administered at a dose of 300-400 mg/kg/month. Clinical outcome was the incidence of new infectious complications and deadly infections during a 6-month follow up. Results Distribution of solid organ recipients was as follows: Heart 37, liver 10, kidney 13. The incidente of re-infection was significantly higher in patients with HGG that were not treated with IVIG as compared with IVIG-treated patients (78.6% vs 28.1%, two-sided chi-square test pInstituto de Salud Carlos III. Project FIS Clinical Trial EC11084. With participation of FEDER funds. A way of making Europe.
- 1 July 2018
- Published by Wolters Kluwer Health in Transplantation
- Vol. 102 (Supplement) , S84
Intravenous Immunoglobulin Replacement Therapy in Solid Organ Transplantation with Severe Infections and Secondary Antibody Deficiency
Background Secondary antibody deficiency is a risk factor of severe infection in solid organ transplantation. Very few studies have previously evaluated the potential role of IgG replacement in solid organ recipients with IgG hypogammaglobulinemia (HGG) at the time of a severe infectious complication. We evaluated the impact of therapeutic intervention of intravenous immunoglobulin (IVIG) in solid organ recipients with severe infections and HGG on clinical outcomes. Methods Retrospective analysis of prospectively collected data of 60 patients in a single center. All patients were hospitalized because of severe infections or developed a severe infection during a hospitalization in the post-transplantation period (June 2015-June 2017) and were found to have HGG (serum IgG750 mg/dL) and 28 patients were treated with only conventional antimicrobial therapy. IVIG was administered at a dose of 300-400 mg/kg/month. Clinical outcome was the incidence of new infectious complications and deadly infections during a 6-month follow up. Results Distribution of solid organ recipients was as follows: Heart 37, liver 10, kidney 13. The incidente of re-infection was significantly higher in patients with HGG that were not treated with IVIG as compared with IVIG-treated patients (78.6% vs 28.1%, two-sided chi-square test pInstituto de Salud Carlos III. Project FIS Clinical Trial EC11084. With participation of FEDER funds. A way of making Europe.
- Open Access
- 1 May 2017
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 36 (5) , 529-539
Evaluation of humoral immunity profiles to identify heart recipients at risk for development of severe infections: A multicenter prospective study
- 1 May 2017
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 36 (5) , 529-539
Open AccessEvaluation of humoral immunity profiles to identify heart recipients at risk for development of severe infections: A multicenter prospective study
- 1 November 2016
- Published by Elsevier in Transplantation Proceedings
- Vol. 48 (9) , 3027-3029
Potential Immunomodulatory Role of Specific Anticytomegalovirus Intravenous Immunoglobulin in Heart Recipients
- 1 November 2016
- Published by Elsevier in Transplantation Proceedings
- Vol. 48 (9) , 3027-3029
Potential Immunomodulatory Role of Specific Anticytomegalovirus Intravenous Immunoglobulin in Heart Recipients
- 17 September 2016
- Published by Wiley in Transplant Infectious Disease
- Vol. 18 (6) , 832-843
Early intravenous immunoglobulin replacement in hypogammaglobulinemic heart transplant recipients: results of a clinical trial
Background: Immunoglobulin G (IgG) hypogammaglobulinemia (HGG) is a risk factor for development of severe infections after heart transplantation. We performed a clinical trial to preliminarily evaluate the efficacy and safety of early administration of intravenous immunoglobulin (IVIG) for prevention of severe infection in heart recipients with post‐transplant IgG HGG.Methods: Twelve heart recipients with IgG HGG detected in a screening phase of the clinical trial (IgG 750 mg/dL. IgG and specific antibody titers to distinct microorganisms were tested during follow‐up. The primary outcome measure was development of severe infection during the study period. Data on the primary outcome were matched with those of 13 recipients with post‐transplant HGG who were not included in the clinical trial and with those of 11 recipients who did not develop HGG during the same study period.Results: Mean time to detection of HGG was 15 days. IgG and specific antibody reconstitution (anti‐cytomegalovirus, anti‐Haemophilus influenza, and anti‐hepatitis B surface antigen antibodies) was observed in IVIG‐treated patients. Severe infection was detected in 3 of 12 (25%) IVIG‐treated recipients, in 10 of 13 (77%) HGG non‐IVIG patients, and in 2 of 11 (18%) non‐HGG patients (log‐rank, 15.31; P=.0005). No severe IVIG‐related side effects were recorded.Conclusion: Data from this study demonstrate that prophylactic IVIG replacement therapy safely modulates HGG and specific antimicrobial antibodies. Our data also preliminarily suggest that IVIG replacement therapy might decrease the incidence of severe infection in heart recipients with HGG.
- 17 September 2016
- Published by Wiley in Transplant Infectious Disease
- Vol. 18 (6) , 832-843
Early intravenous immunoglobulin replacement in hypogammaglobulinemic heart transplant recipients: results of a clinical trial
Background: Immunoglobulin G (IgG) hypogammaglobulinemia (HGG) is a risk factor for development of severe infections after heart transplantation. We performed a clinical trial to preliminarily evaluate the efficacy and safety of early administration of intravenous immunoglobulin (IVIG) for prevention of severe infection in heart recipients with post‐transplant IgG HGG.Methods: Twelve heart recipients with IgG HGG detected in a screening phase of the clinical trial (IgG 750 mg/dL. IgG and specific antibody titers to distinct microorganisms were tested during follow‐up. The primary outcome measure was development of severe infection during the study period. Data on the primary outcome were matched with those of 13 recipients with post‐transplant HGG who were not included in the clinical trial and with those of 11 recipients who did not develop HGG during the same study period.Results: Mean time to detection of HGG was 15 days. IgG and specific antibody reconstitution (anti‐cytomegalovirus, anti‐Haemophilus influenza, and anti‐hepatitis B surface antigen antibodies) was observed in IVIG‐treated patients. Severe infection was detected in 3 of 12 (25%) IVIG‐treated recipients, in 10 of 13 (77%) HGG non‐IVIG patients, and in 2 of 11 (18%) non‐HGG patients (log‐rank, 15.31; P=.0005). No severe IVIG‐related side effects were recorded.Conclusion: Data from this study demonstrate that prophylactic IVIG replacement therapy safely modulates HGG and specific antimicrobial antibodies. Our data also preliminarily suggest that IVIG replacement therapy might decrease the incidence of severe infection in heart recipients with HGG.
- 1 February 2016
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 113, 50-53
Peripheral blood T- and B-cell immunophenotypic abnormalities in selected women with unexplained recurrent miscarriage
- 1 February 2016
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 113, 50-53
Peripheral blood T- and B-cell immunophenotypic abnormalities in selected women with unexplained recurrent miscarriage